Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-951 vs Oral LD/CD in Advanced Parkinson's Disease
NCT04380142Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of esketamine in Parkinson's disease (PD) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Change From Baseline to Week 12 in Average Daily Normalized 'On' Time Without Troublesome Dyskinesia. Started Oct 2020; status: completed.
02
Drugs
esketamine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04380142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04380142.